Patents by Inventor Reijo Laaksonen
Reijo Laaksonen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11940453Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.Type: GrantFiled: February 10, 2022Date of Patent: March 26, 2024Assignee: ZORA BIOSCIENCES OYInventor: Reijo Laaksonen
-
Patent number: 11474116Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.Type: GrantFiled: December 12, 2018Date of Patent: October 18, 2022Assignee: ZORA BIOSCIENCES, OYInventor: Reijo Laaksonen
-
Publication number: 20220163547Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.Type: ApplicationFiled: February 10, 2022Publication date: May 26, 2022Inventor: Reijo Laaksonen
-
Publication number: 20220003791Abstract: The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.Type: ApplicationFiled: December 6, 2019Publication date: January 6, 2022Inventors: Mika HILVO, Reijo LAAKSONEN
-
Publication number: 20210239719Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: ApplicationFiled: February 17, 2021Publication date: August 5, 2021Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Patent number: 10955427Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: GrantFiled: March 4, 2019Date of Patent: March 23, 2021Assignee: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Publication number: 20210003598Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.Type: ApplicationFiled: December 16, 2019Publication date: January 7, 2021Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Publication number: 20200348316Abstract: The present disclosure is related to the field of diabetes diagnostics. It introduces novel biomarkers that can be used to predict diabetes and detect presence of the disease. In addition, novel fatty acid biomarkers are presented.Type: ApplicationFiled: November 20, 2018Publication date: November 5, 2020Inventors: Kevin HUYNH, Dianna MAGLIANO, Jonathan SHAW, Mika HILVO, Reijo LAAKSONEN, Peter MEIKLE
-
Patent number: 10551394Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.Type: GrantFiled: December 7, 2017Date of Patent: February 4, 2020Assignee: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Publication number: 20200003794Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: ApplicationFiled: March 4, 2019Publication date: January 2, 2020Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Publication number: 20190113531Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.Type: ApplicationFiled: December 12, 2018Publication date: April 18, 2019Inventor: Reijo Laaksonen
-
Patent number: 10261101Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: GrantFiled: November 3, 2017Date of Patent: April 16, 2019Assignee: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Publication number: 20190086386Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.Type: ApplicationFiled: November 16, 2018Publication date: March 21, 2019Inventors: Marko Sysi-Aho, Mika Hilvo, Kim Ekroos, Reini Hurme, Reijo Laaksonen, Virve Vaeisaenen
-
Patent number: 10197582Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV complications such as AMI, ACS, stroke, and CV death by determining the concentrations of at least one ceramide of Group A and at least one ceramide of Group B in a biological sample and comparing those concentrations to a control. Finding a decreased concentration of at least one Group A ceramide and an increased concentration of at least one Group B ceramide indicates that the subject has an increased risk of developing one or more CV complications. Also provided are a newly identified subset of ceramide molecules, labelled versions thereof, and kits and compositions comprising the same for use in predicting and/or diagnosing CV complications.Type: GrantFiled: May 19, 2016Date of Patent: February 5, 2019Assignee: ZORA BIOSCIENCES, OYInventor: Reijo Laaksonen
-
Patent number: 10184932Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.Type: GrantFiled: December 7, 2016Date of Patent: January 22, 2019Assignee: Zora Biosciences OYInventors: Mika Hilvo, Reini Hurme, Reijo Laaksonen, Virve Vaeisaenen
-
Publication number: 20180321266Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.Type: ApplicationFiled: December 7, 2017Publication date: November 8, 2018Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Publication number: 20180067138Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: ApplicationFiled: November 3, 2017Publication date: March 8, 2018Inventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Patent number: 9863965Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: GrantFiled: July 14, 2016Date of Patent: January 9, 2018Assignee: Zora Biosciences OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Patent number: 9857386Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.Type: GrantFiled: August 25, 2016Date of Patent: January 2, 2018Assignee: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen
-
Patent number: 9841431Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: GrantFiled: October 5, 2015Date of Patent: December 12, 2017Assignee: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Riikka Katainen